NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 1 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,850 | +184.7% | 27,898 | +589.2% | 0.00% | – |
| Q2 2023 | $10,485 | +55084.2% | 4,048 | -15.2% | 0.00% | -100.0% |
| Q1 2023 | $19 | +18.8% | 4,771 | +56.3% | 0.00% | 0.0% |
| Q4 2022 | $16 | -100.0% | 3,052 | -46.2% | 0.00% | 0.0% |
| Q3 2022 | $74,000 | +155.2% | 5,674 | +154.1% | 0.00% | 0.0% |
| Q2 2022 | $29,000 | +81.2% | 2,233 | +120.0% | 0.00% | – |
| Q1 2022 | $16,000 | +23.1% | 1,015 | +37.9% | 0.00% | – |
| Q4 2021 | $13,000 | -90.1% | 736 | -88.2% | 0.00% | -100.0% |
| Q3 2021 | $131,000 | +138.2% | 6,235 | +123.2% | 0.00% | +200.0% |
| Q2 2021 | $55,000 | +12.2% | 2,793 | +64.1% | 0.00% | 0.0% |
| Q1 2021 | $49,000 | +32.4% | 1,702 | +37.6% | 0.00% | 0.0% |
| Q4 2020 | $37,000 | -62.2% | 1,237 | -80.0% | 0.00% | 0.0% |
| Q3 2020 | $98,000 | +27.3% | 6,190 | +58.2% | 0.00% | -66.7% |
| Q2 2020 | $77,000 | +381.2% | 3,914 | +195.6% | 0.00% | +200.0% |
| Q1 2020 | $16,000 | 0.0% | 1,324 | +23.5% | 0.00% | 0.0% |
| Q2 2019 | $16,000 | – | 1,072 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |